Clinical Trials

DermatologicHead & NeckSarcoma

420 enrolled

Eyelid Squamous Cell Carcinoma

NCT06900595 2026-03-18

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

48 enrolled

Endocrine

Adrenocortical Carcinoma

NCT06931717 2026-03-18

ARCH

390 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07281417 2026-03-18

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

Phase 1 Not yet recruiting

108 enrolled

Sinonasal Squamous Cell Carcinoma

NCT07422363 2026-03-18

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

30 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT06508463 2026-03-16

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Phase 1 Recruiting

21 enrolled

Lymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05401786 2026-03-12

RAD-IO

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06981325 2026-03-11

CEMI-first

34 enrolled

Carcinoma, Basal Cell, Skin Neoplasms

NCT06171750 2026-03-06

ANCHOR

Phase 1 Recruiting

97 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Skin Neoplasms

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Phase 2 Suspended

126 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06412198 2026-03-06

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

31 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT06699602 2026-03-04

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

10 enrolled

Carcinoma, Renal Cell

NCT07450183 2026-03-04

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

33 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04988074 2026-03-03

MINIMA

32 enrolled

HPV-Related Squamous Cell Carcinoma

NCT07223541 2026-03-02

LAG-BOOST

72 enrolled

Carcinoma, Renal Cell

NCT05125016 2026-02-27

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

370 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT03565783 2026-02-25

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

44 enrolled

DermatologicHead & Neck

Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck

NCT06585410 2026-02-25

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

369 enrolled

Skin Neoplasms

NCT07433673 2026-02-25

GAP Cemi

20 enrolled

Gastrointestinal

Rectal Neoplasms

NCT06918132 2026-02-24

N-PLANC

60 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03088540 2026-02-23

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

712 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06219317 2026-02-23

ICARS

136 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07188896 2026-02-23

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

120 enrolled

Carcinoma, Renal Cell

NCT06855212 2026-02-20

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

21 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06246916 2026-02-19

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

560 enrolled

Melanoma

NCT06943664 2026-02-18

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

27 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07418931 2026-02-18

CECYDE

108 enrolled

Phase 1/2 Active not recruiting

Advanced Squamous Non-Small Cell Lung Cancer

NCT05882734 2026-02-17

Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

61 enrolled

Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT06651593 2026-02-17

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

40 enrolled

Other solid neoplasm

Solid Tumors

NCT07414992 2026-02-17

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

44 enrolled

Phase 1 Active not recruiting

Urinary Bladder Neoplasms

NCT03233139 2026-02-12

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

146 enrolled

Advanced Malignancies

NCT06465329 2026-02-12

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

120 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

20 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06656598 2026-02-11

SPORADIC

152 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07234058 2026-02-11

LAG-MAPS

Other solid neoplasmThoracic

126 enrolled

Mesothelioma, Malignant

NCT07404332 2026-02-11

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Phase 1 Not yet recruiting

35 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

46 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06190951 2026-02-10

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

151 enrolled

Melanoma, Skin Neoplasms

NCT07360743 2026-02-10

META-1

275 enrolled

Phase EARLY_PHASE1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

22 enrolled

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT04913220 2026-02-04

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Phase 1/2 Terminated

46 enrolled 22 charts

Melanoma

NCT07224022 2026-02-04

NACho

24 enrolled

Gastrointestinal

Colonic Neoplasms

NCT07387198 2026-02-04

NeoMatryx

135 enrolled

Phase 1 Active not recruiting

Skin Neoplasms, Carcinoma, Merkel Cell

NCT06469281 2026-02-03

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Phase 1 Recruiting

90 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02651662 2026-02-02

CLIO-1

105 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT04626635 2026-02-02

COMBINE-EGFR-1

Phase 1/2 Active not recruiting

933 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT03491683 2026-01-28

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

52 enrolled

CNS

Glioblastoma

NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

60 enrolled